EntryPoint Capital’s Nuvation Bio NUVB Stock Holding History

EntryPoint Capital’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-79,922	Closed	-$183K	–	894
2024 Q3	$183K	Buy	+79,922	New	+$244K	0.1%	492

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

EntryPoint Capital's NUVB Position: Q4 2024 in Review

EntryPoint Capital sold out of Nuvation Bio (NUVB) in Q4 2024, closing a stake of 79,922 shares — an estimated $183K sold.

EntryPoint Capital first reported a position in NUVB in Q3 2024 and held it in 1 quarter. The position peaked at $183K in Q3 2024. 160 funds tracked by Wall St. Rank hold NUVB as of Q4 2024.

EntryPoint Capital reported no remaining Nuvation Bio position as of Q4 2024 after selling out during the quarter.
EntryPoint Capital sold 79,922 Nuvation Bio shares in Q4 2024, an estimated $183K.
EntryPoint Capital first reported a position in Nuvation Bio in Q3 2024 and held it in 1 quarter.
EntryPoint Capital's Nuvation Bio position peaked at $183K in Q3 2024.
160 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.